Disease Education Resources
Oncology
Explore our library of Lilly-created medical education resources.
Breast Cancer - Early
CDK4/6i Trials in HR+, HER2- EBC: Evolution of Data
Presents the evolution of clinical data for the approved CDK4/6 inhibitors in HR+, HER2- early breast cancer
CDK4/6i Trials in HR+, HER2- EBC: Summary of Efficacy and Safety
Presents the summary of efficacy and safety in the CDK4/6i trials for HR+, HER2- early breast cancer
Dr. Rugo: Identification and Treatment of Patients with HR+, HER2- EBC at a High Risk of Recurrence
Watch Dr. Rugo as she shares vital insights on identifying and managing patients with HR+, HER2- early breast cancer at high risk of recurrence. Learn about unmet needs, high-risk features, and treatment options to help individualize patient care.
Dr. Wander: CDK4/6 Inhibitor Clinical Trial Designs in High-Risk HR+, HER2- EBC
Join Dr. Wander as he reviews trial designs for FDA-approved CDK4/6 inhibitors in high-risk HR+, HER2- early breast cancer (EBC). Understanding these studies is essential for selecting optimal treatment for patients.
Dr. Wander: CDK4/6 Inhibitor Efficacy and Safety Results in High-Risk HR+, HER2- EBC
Join Dr. Wander as he reviews safety and efficacy data for FDA-approved CDK4/6 inhibitors in high-risk HR+, HER2- EBC. This video equips HCPs with insights to enhance understanding and improve clinical decision-making for patients
HR+, HER2- Early Breast Cancer
Educational site offering guidance to HCPs on the identification and management of patients with high-risk early breast cancer.
Explore the role of CDK4/6 inhibitors + endocrine therapy in high-risk HR+, HER2- early breast cancer. This deck addresses unmet needs, supporting data, and strategies to reduce recurrence risk, empowering evidence-based decisions for your patients.
Patient Education Resources
Explore our library of patient based education materials to aid in HCP to patient interactions.